# Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study

> **NCT02914626** · PHASE3 · UNKNOWN · sponsor: **LEANDRO CABRAL ZACHARIAS** · enrollment: 28 (estimated)

## Conditions studied

- Glaucoma, Neovascular
- Ranibizumab

## Interventions

- **DRUG:** Intravitreal ranibizumab

## Key facts

- **NCT ID:** NCT02914626
- **Lead sponsor:** LEANDRO CABRAL ZACHARIAS
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2017-10
- **Final completion:** 2018-10
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2016-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02914626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02914626, "Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02914626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*